
Bridging science and hope for genetic diseases
BridgeBio (NASDAQ: BBIO) is a biopharmaceutical company headquartered in Palo Alto, California, focused on developing innovative medicines for genetic diseases. With a pipeline of over 15 programs, BridgeBio aims to address unmet medical needs for rare genetic conditions, leveraging advancements in ...
BridgeBio offers competitive salaries, equity options, comprehensive health benefits, and generous PTO policies. Employees also enjoy a flexible work ...
BridgeBio fosters a culture of innovation and collaboration, emphasizing the importance of scientific rigor and entrepreneurial spirit. The company va...

BridgeBio • Washington DC
BridgeBio is seeking an Executive Director for U.S. Public Policy to shape policy strategies related to Medicare, Medicaid, and payment models. This role requires extensive experience in public policy and leadership in the biopharma sector.
You have a proven track record in public policy, particularly in healthcare, with a focus on Medicare and Medicaid. Your experience includes developing and implementing strategies that influence access and reimbursement in the biopharma industry. You are adept at navigating complex regulatory environments and have a deep understanding of the implications of policy decisions on patient access and innovation.
You possess strong leadership skills, having advised executive teams and shaped organizational strategies. Your ability to communicate effectively with diverse stakeholders, including government agencies and industry partners, sets you apart. You thrive in environments that require innovative thinking and a willingness to challenge the status quo.
Your background includes a deep understanding of the healthcare landscape, particularly in relation to payment policy and coverage. You are passionate about improving patient access to life-changing medicines and have a history of advocating for policies that support innovation in the biopharma sector.
Experience working with CMS and HHS is highly desirable, as is familiarity with the intricacies of payment models and their impact on healthcare delivery. A network of contacts within government and industry will be beneficial in this role, as will a strong analytical mindset to assess policy impacts.
As the Executive Director, U.S. Public Policy, you will lead the development of BridgeBio's public policy strategy, focusing on Medicare, Medicaid, and payment models. You will be responsible for shaping policy positions that influence access and reimbursement for the company's portfolio of innovative therapies. Your role will involve advising executive leadership on policy implications and guiding the implementation of strategies across the organization.
You will engage with government officials, industry stakeholders, and advocacy groups to promote policies that enhance patient access to biopharmaceutical innovations. Your expertise will be crucial in navigating the regulatory landscape and ensuring that BridgeBio's interests are represented in policy discussions.
You will also analyze and interpret policy developments, providing insights that inform the company's strategic direction. Collaborating with cross-functional teams, you will ensure that public policy considerations are integrated into business planning and decision-making processes.
BridgeBio offers a competitive salary range of $305,000 to $350,000 USD, reflecting the seniority and importance of this role. You will have the opportunity to work alongside some of the most respected minds in the industry, contributing to groundbreaking advancements in rare disease treatment. Our culture encourages innovation and collaboration, empowering you to make a significant impact on patient access and biopharma innovation.
We believe in fostering a diverse and inclusive workplace where every team member can thrive. You will have access to professional development opportunities and the chance to shape the future of healthcare policy in a meaningful way.
Apply now or save it for later. Get alerts for similar jobs at BridgeBio.